Medical News

RSS

NeuroTherm receives US patent for RF generator

NeuroTherm is pleased to be recognized by the United States Patent Office as the first company worldwide to develop and release a multiple output radiofrequency generator used in the treatment of chronic pain, ref. US Patent No. 7,574,257.

23 Sep 2009

Comparing U.S. health insurance to other developed nations: Some surprises

USA Today reports on "how other developed countries provide and pay for health care compared with the U.S. system, based on the most recent information available." For example, they report that "Germany requires people making less than about $70,000 a year to have health insurance, which is operated by more than 200 competing, non-profit insurance companies."

23 Sep 2009

Interactive campaign to raise awareness on breast cancer

This week, Yoplait, in partnership with Susan G. Komen for the Cure, launched Know Your Girls, an interactive campaign that empowers young women to learn about breast cancer risk factors -- and then share this knowledge with their circle of friends.

23 Sep 2009

Myths surrounding the hybrid model of concierge care

With an estimated 50 million people potentially entering the healthcare system if coverage for the uninsured is expanded, industry leaders nationwide are concerned about how to provide primary care coverage to new and existing patients. Research indicates that many areas of the country already have severe shortages of primary care physicians (PCP); many in primary care are moving to other specialties or limiting new patients; and the number of medical students entering primary care programs continues to dwindle.

23 Sep 2009

Nukepills replenishes its stock of N95 face masks for flu season

Nukepills.com today announced the replenishment of its stock of N95 Particulate Masks just in time for the upcoming flu season. A deluge of online orders in May of this year, in response to media stories of the Swine Flu Virus (H1N1), depleted the company's large inventory in just a few days.

23 Sep 2009

Eldorado and WellDyneRx collaborate to create and market integrated claims processing software

Eldorado Computing, Inc. (ELDORADO), a leading provider of health benefit and claims management platforms, and WellDyneRx Inc., a national pharmacy benefits management (PBM) company, announced today that they are collaborating to create and market integrated claims processing software and PBM services to payers.

23 Sep 2009

Stay Fresh textiles technology from Quick-Med

Quick-Med Technologies, Inc. (OTCBB:QMDT) announced today the development of a proprietary Stay Fresh™ technology and that the Company is seeking partners to commercialize this revolutionary new technology in key segments of the textile market.

23 Sep 2009

New palate reconstruction technique for post tonsil cancer surgery

A new technique for reconstructing the palate after surgery for tonsil cancer maintained patients' ability to speak clearly and eat most foods, a new study shows.

23 Sep 2009

ART's new generation Optix MX3 optical molecular imaging system unveiled

ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, today unveiled a new generation of its optical molecular imaging system, called Optix® MX3, at the Industry Workshop opening event of the World Molecular Imaging Congress.

23 Sep 2009

Interleukin Genetics reports positive results from clinical study on weight management

Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today top-line positive results from a retrospective clinical study on weight management using patients who participated in a diet study previously reported in the Journal of the American Medical Association.

23 Sep 2009

NASDAQ halts trading in CombinatoRx's common stock

CombinatoRx, Incorporated (NASDAQ: CRXX) announced that NASDAQ has halted trading in the Company’s common stock today.

23 Sep 2009

Alimera Sciences starts pilot study of Iluvien intravitreal insert

Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien(R) in patients with macular edema secondary to retinal vein occlusion.

23 Sep 2009

FDA accepts Sangamo's IND for repeat-dosing in Phase 1 clinical trial of SB-728-T ZFN-based therapeutic

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.

23 Sep 2009

Congressional Black Caucus Spouses to host 4th Annual Community Health Breakfast

On September 24, 2009, the Congressional Black Caucus Spouses will continue their tradition of direct community involvement by hosting its 4th Annual Community Health Breakfast at So Others Might Eat (SOME) from 7 a.m. - 10:30 a.m., 71 O Street, NW, Washington, D.C.

23 Sep 2009

ID Analytics' risk management solutions available on U.S. GSA Schedule

ID Analytics, Inc., the leader in on-demand identity intelligence, announced today its risk management solutions are now available on its' U.S. General Services Administration (GSA) Schedule.

23 Sep 2009

OMA's first ever media campaign to focus on the issue of patient safety

The Ontario Medical Association (OMA) Section on General & Family Practice (SGFP) held a media conference today to announce the launch of its first ever media campaign.

23 Sep 2009

Pluristem commences dosing in Phase I clinical trial for the treatment of critical limb ischemia

Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) today announced the dosing of the first patient in the U.S. with its placenta-derived stem cell product, PLX-PAD, the Company’s leading candidate, in a Phase I clinical trial for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

23 Sep 2009

Adolor acquires exclusive worldwide rights to OpRA III

Adolor Corporation (NasdaqGM:ADLR) today announced that it has acquired from Eli Lilly and Company (“Lilly”) the exclusive worldwide rights to OpRA III, a clinical-stage product candidate.

23 Sep 2009

First Edition: September 23, 2009

Today's headlines mark the opening day of the Senate Finance Committee's health bill mark up as well as a new round up of changes to the chairman's mark.

23 Sep 2009

Clinical informatics solution for health care providers and pharmaceutical firms

Humedica, a next-generation health care informatics company, today announced the company’s official launch, along with the previous completion of its $30 million round of venture capital and the roll-out of its ground-breaking clinical analytics platform.

23 Sep 2009